Longjumeau, April 21, 2015

(in millions of euros) 2014 2015 % change
    
Sales as of 31 March 42.1 40.4-4.0%
Pharmaceutical Synthesis 27.1 25.7 -5.1%
Fine Speciality Chemicals 14.9 14.6 -2.1%

The first quarter of 2015 was 4% down on the first quarter of 2014, nonetheless in line with forecasts for a sharp rise in group sales for 2015.

Pharmaceutical synthesis

Activities in the first quarter of 2015 were affected by an imbalance between first and second-quarter sales in 2015.

Fine specialty chemicals

Growth in Performance Fine Chemicals and New Technologies activities in the first quarter of 2015 did not make up for the downturn in Fragrances-Flavors-Cosmetics.

Thanks to the increase of its order book PCAS Group is able to confirm significant growth prospects of its sales in 2015, both in Pharmaceutical Synthesis and in Fine Specialty Chemicals.

Next meeting:
2015 Shareholder's Meeting on April 22, 2015 at 10 a.m.  in Longjumeau


About PCAS

Founded in 1962, PCAS is an international fine and specialty chemicals group (€166 million net sales in 2014) that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.

Financial reporting: Vincent Touraille - Eric Moissenot | T +33 (0)1 69 09 77 85 | www.pcas.com

PCAS_CAT1_2015_EN:
http://hugin.info/143512/R/1913044/683075.pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire
HUG#1913044